MedCity News March 14, 2025
Frank Vinluan

MeiraGTx’s gene therapy for Parkinson’s disease will enter Phase 3 testing under a new joint venture the biotech is forming with Hologen, a generative AI startup. The joint venture has up to $230 million in committed capital; MeiraGTx gets additional cash for its pipeline.

MeiraGTx has one gene therapy in a potentially pivotal clinical trial for cancer patients and another gene therapy ready to start Phase 3 in Parkinson’s disease. Completing the studies will be expensive and raising money is challenging with stock market volatility increasing by the day. MeiraGTx found another way to fund both studies. It’s teaming up with an artificial intelligence startup to form a joint venture responsible for the Parkinson’s program, supported by up to $230...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma / Biotech, Technology
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
Ensitrelvir Shows Promise Preventing COVID-19 Post Exposure
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal

Share This Article